The IBMP ELISA IgA/IgM/IgG COVID-19 kit has similar or better diagnostic performance than the commercial assays investigated in this study, high intra-assay reproducibility, and a high detection of seroconversion at an early stage of the infection. This evidence concerns the gene CD79A and infection.